Pulmatrix
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
945 Concord St Ste 1217, Framingham, Mas...Phone Number
(888) 355-4440Website
www.pulmatrix.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pulmatrix
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology. The Company's proprietary product pipeline includes treatments for serious lung diseases, such as allergic bronchopulmonary aspergillosis (ABPA), Chronic Obstructive Pulmonary Disease (COPD), and neurologic disorders such as acute migraine. Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.Explore more
Pulmatrix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pulmatrix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Pulmatrix is spiking on competitors!
Pulmatrix, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pulmatrix has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pulmatrix has new funding data
Earning: See what the market has to say on Pulmatrix recently announced quarterly report
Product Launch: Get notified when Pulmatrix launches new products
Congratulate Masked Content for being promoted to Masked Content at Pulmatrix
Click to see if Pulmatrix had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Pulmatrix
Find more new buyers
Compare Similar Companies to Pulmatrix
Compare insights from companies similar to Pulmatrix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Pulmatrix
$7.8M
1-10
Private
$157.3M
2013
RC
Russell ClaytonStrategic Advisor & Medical Director, Clinical Programs
Company Profile Activity
Activity Insights
Pulmatrix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pulmatrix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pulmatrix.
Pulmatrix financials insights
Gather financial insights about Pulmatrix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$20.5M
2015
Share Placement
$10M
2017
Stock Offering
$9.7M
2018
Stock Offering
$15.9M
Stock Offering
$3M
2019
Multiple Rounds
$20.3M
2020
Stock Offering
$8M
2026
Private Equity
$1M
Pulmatrix Tech Stack
A closer look at the technologies used by Pulmatrix
Most Recent Scoops
Funding
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Pulmatrix News & Media
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of...Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related disease FRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq:...Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix advances existing discussions on alternative merger opportunities -...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pulmatrix
Sign Up For FreeTo access detailed company insights
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology. The Company's proprietary product pipeline includes treatments for serious lung diseases, such as allergic bronchopulmonary aspergillosis (ABPA), Chronic Obstru... Read More
